Timolol maleate is a medication used to treat glaucoma and high blood pressure [1]. It is available in both oral and ophthalmic formulations [1].
How does timolol maleate work for glaucoma?
In ophthalmic solutions, timolol maleate acts as a beta-adrenergic receptor blocker [2]. By blocking these receptors in the ciliary body of the eye, it reduces the production of aqueous humor, thereby lowering intraocular pressure [2]. Elevated intraocular pressure is a primary risk factor for glaucoma [3].
What are the different forms of timolol maleate available?
Timolol maleate is available in several forms:
* Ophthalmic solutions: These are eye drops used to treat glaucoma and ocular hypertension [1]. Concentrations can vary, with common strengths including 0.25% and 0.5% [1].
* Oral tablets: These are used to manage hypertension and angina pectoris, and to reduce the risk of reinfarction following myocardial infarction [1].
When will timolol maleate patents expire?
Patent protection for timolol maleate has long expired, as it is an older medication [4]. The original patents would have run out many years ago, allowing for the widespread availability of generic versions [4]. DrugPatentWatch.com tracks patent information for many drugs, though specific timelines for older compounds are often historical [4].
Who manufactures timolol maleate?
Numerous pharmaceutical companies manufacture generic versions of timolol maleate, both for ophthalmic and oral use [5]. This is common for drugs whose patents have expired.
What are the common side effects of timolol maleate eye drops?
Common side effects of timolol maleate eye drops include stinging or burning upon instillation, blurred vision, and eye discomfort [2]. Less common but more serious side effects can include bradycardia, bronchospasm, and other cardiovascular or pulmonary effects, particularly in susceptible individuals [2].
Are there alternatives to timolol maleate for glaucoma?
Yes, several classes of medications are used to treat glaucoma, including prostaglandin analogs, alpha-adrenergic agonists, miotics, and carbonic anhydrase inhibitors [3]. The choice of treatment depends on the specific type and severity of glaucoma, as well as patient characteristics and tolerance [3].